P-31 NMR-STUDIES ON THE INTERACTION OF MORPHOLINYL ANTHRACYCLINES AND RELATED-COMPOUNDS WITH D(CGTACG)2 - THERMODYNAMIC AND KINETIC-PARAMETERS

被引:10
作者
BORTOLINI, R
MAZZINI, S
MONDELLI, R
RAGG, E
ULBRICHT, C
VIOGLIO, S
PENCO, S
机构
[1] UNIV MILAN,DIPARTIMENTO SCI MOLEC AGROALIMENTARI,VIA CELORIA 2,I-20133 MILAN,ITALY
[2] FARMITALIA CARLO ERBA RIC,MILAN,ITALY
关键词
D O I
10.1007/BF03162548
中图分类号
O64 [物理化学(理论化学)、化学物理学]; O56 [分子物理学、原子物理学];
学科分类号
070203 ; 070304 ; 081704 ; 1406 ;
摘要
P-31 NMR spectroscopy has been used to study the intercalation of the anthracyclines doxorubicin 1, daunorubicin 2, 4-demethoxydaunorubicin 3, morpholinodoxorubicin 4, methoxymorpholinodoxorubicin 5 and 9-deoxydaunorubicin 6 with the DNA fragment d(CGTACG)2. The individual phosphate resonances of the oligonucleotide were assigned in the free as well as in the intercalated species. The P-31 chemical shift variations allowed us to identify the intercalation sites, which resulted to be the same for all compounds i.e. between the terminal CG base-pairs of the helix (two molecules of drug per duplex). The binding constants, the dissociation rate constants and DELTAG# values have been determined in different conditions of ionic strength and temperature. The kinetic constant (k(off)) of the slow step of the anthracycline/duplex intercalation process has been directly measured by NOE exchange techniques. Binding constants depend on the ionic strength and on the self-association process so greatly, that their use to study by NMR anthracycline/DNA interactions is questionable. On the contrary, the k(off) are not affected by these phenomena and present an interesting trend for 1-6, thus showing that the average life-time of the drug in the intercalation site appears to be important for determining the cytotoxicity and the antimitotic activity.
引用
收藏
页码:71 / 87
页数:17
相关论文
共 27 条
[1]   INTENSELY POTENT MORPHOLINYL ANTHRACYCLINES [J].
ACTON, EM ;
TONG, GL ;
MOSHER, CW ;
WOLGEMUTH, RL .
JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (05) :638-645
[2]  
ANDERSON RD, 1991, CANCER RES, V51, P3930
[3]  
Arcamone F., 1981, DOXORUBICIN ANTICANC
[4]  
Bargiotti A., 1987, US Patent, Patent No. [4,672,057, 4672057]
[5]  
BATTISTINI C, 1989, MAGN RESONANCE CHEM, V27, P640
[6]   SITE AND SEQUENCE SPECIFICITY OF THE DAUNOMYCIN DNA INTERACTION [J].
CHAIRES, JB ;
FOX, KR ;
HERRERA, JE ;
BRITT, M ;
WARING, MJ .
BIOCHEMISTRY, 1987, 26 (25) :8227-8236
[7]   SELF-ASSOCIATION OF DAUNOMYCIN [J].
CHAIRES, JB ;
DATTAGUPTA, N ;
CROTHERS, DM .
BIOCHEMISTRY, 1982, 21 (17) :3927-3932
[8]   STUDIES ON INTERACTION OF ANTHRACYCLINE ANTIBIOTICS AND DEOXYRIBONUCLEIC-ACID - EQUILIBRIUM BINDING-STUDIES ON INTERACTION OF DAUNOMYCIN WITH DEOXYRIBONUCLEIC-ACID [J].
CHAIRES, JB ;
DATTAGUPTA, N ;
CROTHERS, DM .
BIOCHEMISTRY, 1982, 21 (17) :3933-3940
[9]   KINETICS OF THE DAUNOMYCIN DNA INTERACTION [J].
CHAIRES, JB ;
DATTAGUPTA, N ;
CROTHERS, DM .
BIOCHEMISTRY, 1985, 24 (02) :260-267
[10]   A THEORETICAL INVESTIGATION ON THE SEQUENCE SELECTIVE BINDING OF DAUNOMYCIN TO DOUBLE-STRANDED POLYNUCLEOTIDES [J].
CHEN, KX ;
GRESH, N ;
PULLMAN, B .
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 1985, 3 (03) :445-466